069620 — Daewoong Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Market Cap
KR₩2tn
Enterprise Value
KR₩3tn
Revenue
KR₩2tn

Annual income statement for Daewoong Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,152,976	1,280,092	1,375,329	1,422,683	1,570,891
Cost of Revenue
Gross Profit	544,573	638,958	688,167	734,168	822,532
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,066,556	1,189,513	1,223,273	1,326,129	1,338,535
Operating Profit	86,420	90,579	152,056	96,555	232,356
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	19,761	38,330	121,999	56,550	191,833
Provision for Income Taxes
Net Income After Taxes	30,084	39,163	120,003	23,347	192,909
Minority Interest
Net Income Before Extraordinary Items
Net Income	24,506	42,240	121,739	24,735	195,856
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	24,506	42,240	121,739	24,735	195,856
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2,424	4,108	8,224	4,010	15,008
Dividends per Share